AstraZeneca on Tuesday said its neuromuscular treatment had been accepted for priority review in the US.
The submission to the Food and Drug Administration for its Ultomiris drug was based on a positive Phase III trial in which Ultomiris significantly improved functional activities for patients with generalised myasthenia gravis (gMG).
The disease causes damage at the connection point between nerve cells and the muscles they control, leading to a breakdown of communication between the brain and muscles, causing loss of muscle function and severe weakness. The diagnosed prevalence of gMG in the US is estimated at 64,000, AstraZeneca said.
